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COVID-19 (Coronavirus disease 2019) caused by SARS-CoV-2 has become a global pandemic. The World Health Organization (WHO) declared COVID-19 as a pandemic on 11 March 2020. Up until 23 April, 2,649,680 cases have been reported in 185 countries \[<https://coronavirus.jhu.edu/map.html>\]. Studies showed that typical clinical symptoms included cough, sore throat, fever, fatigue, and shortness of breath \[[@CR1]\]. So far, pulmonary manifestations, including interstitial pneumonia, which in its severe course may lead to lung failure and acute respiratory distress syndrome (ARDS/SARS), are the predominant source of morbidity and mortality. However, extrapulmonary manifestations of COVID-19 have been reported with an evolving understanding of their contribution to disease transmission and morbidity. In a Chinese study, up to 27.8% of patients have myocardial injuries that can lead to cardiac dysfunction and arrhythmias \[[@CR2]\]. In addition, Covid-19 has been shown to cause multiple gastrointestinal symptoms with 5% of patients having nausea or vomiting and 3.8--10.1% having diarrhea \[[@CR3]\]. A recent Chinese study showed that more than half of patients (53.42%; 39/73, tested within 14 days) tested positive for SARS-CoV-2 RNA in stool \[[@CR4]\]. Furthermore, SARS-CoV-2 binds angiotensin-converting enzyme 2 (ACE2) protein of the host cell membrane to fuse into the cell for nucleic acid replication; thus, organs expressing the ACE2 protein have been implicated in viral transmission. Immunofluorescence data demonstrated that ACE2 is abundantly expressed in salivary, gastric, duodenal, and rectal epithelia, in addition to hepatic cholangiocytes and pancreas endocrine and exocrine cells, implicating the gastrointestinal tract in COVID-19-related morbidities and SARS-CoV-2 transmission \[[@CR4]--[@CR6]\].

The practice of endoscopy poses special challenges and risks of SARS-CoV-2 transmission to patients and providers, given the evolving role of the gastrointestinal tract in viral transmission and aerosol generation during endoscopic procedures. While the transmission of SARS-CoV-2 through droplet infection by contact with infected persons is clear, the aerosol transmission of SARS-CoV-2 poses additional risks. Droplets are particles above 20 μm in size. They are usually produced with coughs, sneezes, and shouting. Aerosols comprise fine particles under 10 μm. It is not yet clear how far the respective particles are transported in the environment, but it is assumed that aerosols can be moved more easily and further in the air \[[@CR7]\]. One study reported that the virus can remain viable and infectious in aerosols for hours and on surfaces for up to 3 days \[[@CR8]\]. Furthermore, particles smaller than 5 μm can migrate directly into the alveoli, whereas the path of particles larger than 10 μm ends naturally below the glottis in the bronchial tree. This worldwide pandemic has led to a global lockdown in most countries with suspension of elective surgeries and endoscopic procedures during time of infections surge . Therefore, in addition to the protection measures for personnel, there is a need for a clear definition of which bariatric and metabolic endoscopic interventions are defined as time sensitive and should be carried out during a time of infections surge and which interventions can be postponed to minimize the risk of transmission to medical personnel. This is of critical importance, as the Centers for Disease Control and Prevention (CDC) have classified severe obesity (body mass index (BMI) of 40 or higher) and diabetes as risk factors for severe COVID-19 illness \[<https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/groups-at-higherrisk.html>\]. Furthermore, a large case series of sequentially hospitalized patients with confirmed COVID-19 in the USA showed that pre-existing hypertension and/or diabetes were highly prevalent in this cohort and that ventilated patients had high mortality rates \[[@CR9]\].

Recommendations and guidelines are therefore needed to be well prepared to face this pandemic as bariatric endoscopists, in order to mitigate the risk of SARS-CoV-2 transmission to our vulnerable patients and healthcare workers. To formulate our general recommendations, we relied on the recommendations of the Asian Pacific Society for Digestive Endoscopy (APSDE-COVID statements) \[[@CR10]\] and the American Gastroenterological Association (AGA) institute rapid recommendations for gastrointestinal procedures during the COVID-19 pandemic \[[@CR11]\]. Specific recommendations for bariatric endoscopy were empirically formulated based on expert opinion and extrapolated from the aforementioned guidelines.

How Should the Bariatric Endoscopist Triage Procedures (Table [1](#Tab1){ref-type="table"}) {#Sec2}
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Both the APSDE and AGA guidelines call for deferment of elective endoscopies. Bariatric endoscopists are confronted with a wide spectrum of clinical situations where endoscopy could be deemed urgently required to manage a complication of bariatric surgery or remove an implanted bariatric device for treatment or prevention of a complication. Thus, we recommend that all bariatric endoscopy procedural requests be reviewed by an expert bariatric endoscopist and categorized as time sensitive, requiring endoscopy within 8 weeks or not during a time of infections surge. To make an appropriate determination about time sensitivity, consideration should be given to patients' symptoms, which should be ascertained via a telehealth visit when possible. Patients' engagement in decision-making and documentation of informed consent are critical components of the process.Table 1How should the bariatric endoscopist triage procedures?

With increased COVID-19 testing capabilities using both molecular (real-time PCR for active infection) and serologic (ELISA based for previous exposure and immunity), gradual access to semi-urgent and elective endoscopic procedures will increase (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR12]\]. Molecular testing has targeted a combination of the following SARS-CoV-2 genes: nucleocapsid (N), open reading frame 1ab (Orf), envelope (E), and RNA-dependent RNA polymerase (RdRp). Serologic testing detects IgG-class antibodies to SARS-CoV-2 that could be associated with neutralizing antibody activity and potential protective immunity but is not a replacement for molecular testing as a marker of acute infection. It is equally important to understand testing limitations. Peak viral shedding occurs 24 h prior to symptom onset \[[@CR13]\], and molecular testing sensitivity using nasopharyngeal swabs drops 3--5 days post onset of symptoms or as more severe disease migrates into the lower respiratory tract; thus, bronchoalveolar lavage or sputum collection becomes more sensitive \[[@CR14]\] (Table [2](#Tab2){ref-type="table"}). For the serologic test, sensitivity has not yet been tested in patients with mild or asymptomatic infection; however, in hospitalized patients, sensitivity appears low ≤ 7 days after symptom onset and high ≥ 14 days. It is not known, however, if SARS-CoV-2 antibodies confer immunity or at what titer. Thus, it is important to clearly understand testing limitations influenced by the timing of collection, sample type, sample quality, and test performance, prior to developing a pre-procedural testing strategy. The likely optimal testing strategy will be a combination of molecular and serologic testing. The ramp-up period will probably vary by geographic location based on disease prevalence, testing capabilities, and availability of adequate personal protective equipment (PPE). Notably, a new SARS-CoV-2 neutralizing antibody test, in addition to vaccine development efforts, might change the triage and access strategy to elective bariatric endoscopic procedures in the future.Fig. 1Tests for SARS-CoV-2 and potential uses. Adopted from Robin Patel et al. (mBio 2020)Table 2Yield of different SAR-CoV-2 testing methodsCorona testing positivity rates---Journal of American Medical Association (AMA)Si NoType of specimenPositive %1Bronchoalveolar lavage fluid93%2Fibrobronchoscope brush biopsy463Sputum72%4Nasal swabs63%5Pharyngeal swabs32%6Feces29%7Blood1%8Urine0%Adopted from Wang Xu et al. (2020)

Elective bariatric endoscopy procedures that should be delayed \> 8 weeks (GREEN) are as follows:Primary bariatric intervention (implantable gastric and small intestinal devices, gastric remodeling techniques, aspiration therapy, duodenal resurfacing procedures).Revisional bariatric intervention (transoral outlet reduction (TORe), restorative obesity surgery endoscopic (ROSE), endoscopic sleeve gastroplasty revision of laparoscopic sleeve gastrectomy (R-ESG)).Elective removal or adjustment of an implanted gastric or small intestinal device within the approved dwelling time of the device.Elective removal of Orbera, Orbera 360, or Spatz 3 intragastric balloon in asymptomatic patients in the period between 6 to 12 months after implantation. In the case of the Orbera IGB, delaying removal of the 6 months IGB to up to 9 months is acceptable during the pandemic period, if endoscopy access and resources are limited, based on the published literature describing safety, and requires careful patient counseling with periodic telemedical contact with the patient during the extended IGB dwelling time \[[@CR15]\].Elective upward adjustment of the Spatz3 intragastric balloon for enhancing weight loss.Preoperative endoscopic examinations prior to bariatric surgery.Follow-up endoscopic examinations for non-malignant conditions in asymptomatic patients such as non-dysplastic Barrett's esophagus, esophagitis, gastritis, bile reflux, marginal ulceration, fistula, and gastrointestinal strictures.Post-bariatric surgery endoscopic work-up of common complaints such as abdominal pain, gastroesophageal reflux, nausea, vomiting without clinical red flags, or documentation of pathology on radiographic imaging.Elective removal or change of double pig-tail plastic stents that were previously placed for management of a chronic post-bariatric surgery leak and are in a suitable position without associated symptoms.

Semi-urgent bariatric endoscopy procedures that can be considered, provided appropriate informed consent is obtained, risk for SARS-CoV-2 transmission is minimized, and adequate availability of PPE or rapid reliable SARS-Cov-2 testing is ensured. These can proceed in 48 h to ≤ 8 weeks (ORANGE).Scheduled removal of any implantable gastric or small intestinal bariatric device at the manufacturer's recommended removal interval other than the Orbera IGB (see comments in the previous section).Removal of any implantable gastric or small intestinal bariatric device for refractory symptoms.Removal of an implantable gastric or small intestinal device during pregnancy. This should be a multidisciplinary team decision, coordinated and approved by obstetrics and or maternal fetal medicine.Downward volume adjustment of the Spatz3 IGB to manage medically refractory symptoms.TORe or ROSE procedure for treatment of early or late severe dumping syndrome refractory to medical management.Endoscopic surveillance and management of pre-neoplastic or neoplastic conditions with significant risk of progression such as Barrett's esophagus with high-grade dysplasia or intramucosal cancer.Removal or exchange of sponges for vacuum therapy of endoluminal bariatric leaks.Removal or exchange of indwelling self-expanding or lumen-opposing metal stents to manage complications post-bariatric endoscopy or surgery, such as strictures and leaks.Endoscopic management of symptomatic patients with documented anatomical post-bariatric surgery pathology by non-invasive imaging that can be addressed endoscopically, such as strictures.Replacement of non-functioning or leaking A-tube for aspiration therapy.

Urgent bariatric endoscopy procedures that should be considered within 48 h, to treat a condition that threatens the patient's life or results in permanent dysfunction of an organ. Upper or lower endoscopies in this setting should be considered high risk for SARS-Cov-2 transmission and require appropriate precautions and PPE or performance of rapid reliable SARS-Cov-2 testing (RED).Removal of any intragastric device for symptoms of refractory gastric outlet obstruction symptoms, especially with presence of gastric dilation on non-invasive imaging.Removal of migrated prosthesis or migrated/deflated gastric or small intestinal bariatric device within the reach of upper endoscopy. Of note, deflated IGB or double-pigtail plastic stents that have migrated to the small intestines (not within the reach of upper endoscopy) without symptoms of small bowel obstruction can be observed with serial abdominal imaging for self-excretion with defecation. Migration of any prosthesis or device into the small intestines with symptoms of small bowel obstruction will require emergency surgical consultation.Endoscopic management of gastrointestinal bleeding, perforation, acute leaks, and severe stenosis.Endoscopic management of a buried A-tube bumper during aspiration therapy.
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All endoscopic procedures should be considered aerosol-generating and high risk given the potential for coughing and retching during upper endoscopy and the passage of flatus during colonoscopy. In addition, all endoscopic procedures are at risk of generating aerosol and micro-droplets by the very design, function, and leakage of the instruments, valves, ports, and air pressures during inflation and suction. The following measures are adopted from the US joint GI society statement on use of personal protective equipment in GI endoscopy during the COVID-19 pandemic \[<https://gi.org/2020/04/01/joint-gi-society-message-on-ppe-during-covid-19>\].General measures of physical distancing and adequate hand hygiene are of critical importance and need to be practiced diligently, independent of other protective measures.All members of the endoscopy team should wear a full set of PPE, predicated on resource availabilities.The correct sequence of wearing and removing PPE is critical and needs to be understood and practiced and instructions posted (Fig. [2](#Fig2){ref-type="fig"}) \[[@CR16]\].All members of the endoscopy team should wear N95 respirators (or devices with equivalent or higher filtration rates) for all GI procedures performed on patients with known SARS-CoV-2 infection and those with high risk of exposure. Given the high rate of infection transmission from pre-symptomatic individuals, all patients undergoing GI endoscopy in an area of community spread need to be considered "high risk" (Table [3](#Tab3){ref-type="table"}).All healthcare workers should have their N95 respirators fitted by an occupational health specialist prior to the first usage.Staffing of endoscopy rooms should be reduced to the minimum number of individuals necessary to conserve PPE and other resources.In some cases, shortages may require extended and limited reuse of N95 respirators. Guidance is available on how to wear, remove, and store respirators to minimize contamination \[<https://www.cdc.gov/niosh/topics/hcwcontrols/recommendedguidanceextuse.html>\]. Decontamination of N95 respirators with hydrogen peroxide vapor has been approved by the US FDA as a means of reuse in times of limited supply \[<https://www.safety.duke.edu/sites/default/files/N-95_VHP-Decon-Re-Use.pdf>\].Use of Procedural Oxygen Masks (airway masks with apertures for endoscopes) should be considered for all upper endoscopy procedures to decrease aerosolization during these procedures. Intubation should also be considered in these cases to limit ongoing aerosolization. Topical spray anesthetics to numb the throat should be replaced in favor of a lidocaine swallow. Procedures should be performed in a negative pressure room when possible, especially for COVID-19 positive patients, or enough time between procedures should be allocated for complete air circulation and exchange \[<https://www.safety.duke.edu/sites/default/files/N-95_VHP-Decon-Re-Use.pdf>\].For endoscopes used on patients, regardless of COVID-19 status, we recommend continuing standard cleaning endoscopic disinfection and reprocessing protocols.It is important to recognize the limitations of available COVID-19 testing in your facility. According to a recent publication, nasal swabs, pharyngeal swabs, fecal testing, and bronchoalveolar lavage detected 63%, 32%, 29%, and 93% of cases, respectively. Therefore, it is impossible to rely completely on any of these tests \[[@CR14]\] (Table [2](#Tab2){ref-type="table"}).Adopting an incident response mentality is critical to endoscopy leadership during a time when physicians and staff are asked to embrace significantly altered workflows. Standard operating procedures must be established. There should be regular meetings of endoscopy leadership to review relevant information, with frequent scheduled updates provided to faculty and staff. Lastly, having an upstream communication channel to hospital leadership is critical, especially regarding information relevant to the safety of patients and staff \[[@CR17]\].Fig. 2The correct sequence for wearing and removing PPE adopted from the CDCTable 3PPE for bariatric endoscopy during Covid-19 pandemic
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